Our joint paper prepared with Adamed Ltd. "Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance" (Piotr Rozga, Damian Kloska, Sebastian Pawlak, Malgorzata Teska-Kaminska, Marlena Galazka, Katarzyna Bukato, Anna Pieczykolan, Albert Jaworski, Anna Molga, Aleksandra Kopacz, Bogna Badyra, Neli Kachamakova-Trojanowska, Olga Zolnierkiewicz, Marta Targosz-Korecka, Katarzyna Poleszak, Michal Szymanik, Bartlomiej Zerek, Jerzy Pieczykolan, Alicja Jozkowicz, Anna Grochot-Przeczek) has been accepted for publication. Tha paper demonstrates the efficiency of anti-cancer molecule of AD-O51.4, a novel TRAIL-based fusion protein designed by Adamed Ltd, and identifies the mechanisms of its action. On our side, the study was coordinated by Anna Grochot-Przeczek.
Comments